VIVUS (STU:VIU1) Institutional Ownership : 6.22% (As of May. 14, 2024)

View and export this data going back to . Start your Free Trial

What is VIVUS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, VIVUS's institutional ownership is 6.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, VIVUS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, VIVUS's Float Percentage Of Total Shares Outstanding is 98.72%.

VIVUS Institutional Ownership Historical Data

The historical data trend for VIVUS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Institutional Ownership Chart

VIVUS Historical Data

The historical data trend for VIVUS can be seen below:

	2020-04-30	2020-05-31	2020-06-30	2020-07-31	2020-08-31	2020-09-30	2020-10-31	2020-11-30	2020-12-31	2021-01-31
Institutional Ownership	14.03	14.03	15.48	8.20	8.20	6.22	6.22	6.22	6.22	6.22

VIVUS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines